GLUCAGON-LIKE PEPTIDE-1–BASED THERAPIES IN CARDIOVASCULAR DISEASE: EVIDENCE, MECHANISMS, AND EMERGING CLINICAL APPLICATIONS

Division of Cardiology, Azienda Ospedaliero-Universitaria Policlinico ‘G. Rodolico-San Marco’, University of Catania

GLP-1 receptor agonists were initially developed for glucose-lowering in type 2 diabetes but have shown significant cardiovascular benefits, including reductions in major adverse cardiovascular events. The document reviews large cardiovascular outcome trials and emerging evidence supporting the use of these therapies in obesity and heart failure populations. It highlights the importance of phenotyping in heart failure management and discusses contemporary guidelines recommending GLP-1 therapies for specific patient groups.